 Nicholas Cost
Concepts (372)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 55 | 2024 | 334 | 16.880 |
Why?
| | Wilms Tumor | 29 | 2024 | 69 | 11.130 |
Why?
| | Testicular Neoplasms | 23 | 2023 | 95 | 10.310 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 14 | 2023 | 60 | 6.830 |
Why?
| | Nephrectomy | 31 | 2023 | 162 | 6.680 |
Why?
| | Carcinoma, Renal Cell | 17 | 2023 | 174 | 4.390 |
Why?
| | Lymph Node Excision | 12 | 2023 | 158 | 3.680 |
Why?
| | Rhabdoid Tumor | 5 | 2023 | 80 | 3.110 |
Why?
| | Lymph Nodes | 9 | 2023 | 455 | 2.930 |
Why?
| | Neoplasm Staging | 25 | 2023 | 1223 | 2.790 |
Why?
| | Medical Oncology | 7 | 2023 | 229 | 2.540 |
Why?
| | Orchiectomy | 8 | 2023 | 57 | 2.260 |
Why?
| | Child | 81 | 2024 | 19129 | 2.230 |
Why?
| | Laparoscopy | 11 | 2018 | 417 | 2.200 |
Why?
| | Child, Preschool | 60 | 2023 | 9491 | 2.180 |
Why?
| | Rhabdomyosarcoma | 5 | 2022 | 57 | 2.090 |
Why?
| | Hydronephrosis | 6 | 2019 | 30 | 2.070 |
Why?
| | Adolescent | 64 | 2023 | 18480 | 1.980 |
Why?
| | Lymphatic Metastasis | 12 | 2022 | 307 | 1.860 |
Why?
| | Urologic Surgical Procedures | 8 | 2019 | 94 | 1.840 |
Why?
| | Infant | 50 | 2023 | 8293 | 1.820 |
Why?
| | Urologists | 3 | 2017 | 18 | 1.780 |
Why?
| | Urology | 7 | 2023 | 48 | 1.740 |
Why?
| | Urologic Neoplasms | 4 | 2017 | 25 | 1.700 |
Why?
| | Urinary Bladder | 4 | 2022 | 180 | 1.640 |
Why?
| | Kidney Pelvis | 6 | 2015 | 21 | 1.600 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 81 | 1.580 |
Why?
| | Robotics | 6 | 2015 | 83 | 1.570 |
Why?
| | Male | 94 | 2023 | 57801 | 1.560 |
Why?
| | Humans | 137 | 2024 | 118972 | 1.530 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2021 | 211 | 1.410 |
Why?
| | Lower Urinary Tract Symptoms | 2 | 2021 | 47 | 1.400 |
Why?
| | Organ Sparing Treatments | 4 | 2023 | 31 | 1.350 |
Why?
| | Doxorubicin | 2 | 2021 | 302 | 1.350 |
Why?
| | Ureteral Obstruction | 5 | 2015 | 59 | 1.260 |
Why?
| | Kidney | 9 | 2023 | 1353 | 1.240 |
Why?
| | Urodynamics | 3 | 2019 | 31 | 1.240 |
Why?
| | Urinary Bladder Diseases | 2 | 2019 | 20 | 1.230 |
Why?
| | Pediatrics | 5 | 2019 | 985 | 1.210 |
Why?
| | Prognosis | 18 | 2023 | 3443 | 1.200 |
Why?
| | Retrospective Studies | 43 | 2023 | 12978 | 1.180 |
Why?
| | Tumor Burden | 6 | 2019 | 274 | 1.120 |
Why?
| | Young Adult | 31 | 2023 | 10793 | 1.090 |
Why?
| | Female | 71 | 2023 | 61564 | 1.060 |
Why?
| | Kidney Diseases, Cystic | 3 | 2021 | 20 | 1.040 |
Why?
| | Rhabdomyosarcoma, Embryonal | 2 | 2022 | 17 | 1.040 |
Why?
| | Nephrons | 9 | 2023 | 24 | 1.020 |
Why?
| | Vincristine | 2 | 2022 | 99 | 1.000 |
Why?
| | Urinary Tract | 2 | 2023 | 40 | 0.990 |
Why?
| | Ribonuclease III | 3 | 2021 | 33 | 0.980 |
Why?
| | Practice Patterns, Physicians' | 5 | 2019 | 1200 | 0.960 |
Why?
| | Mixed Tumor, Malignant | 1 | 2023 | 4 | 0.960 |
Why?
| | DEAD-box RNA Helicases | 3 | 2021 | 56 | 0.960 |
Why?
| | Sertoli-Leydig Cell Tumor | 3 | 2021 | 8 | 0.940 |
Why?
| | Biopsy | 5 | 2019 | 1079 | 0.920 |
Why?
| | Hypospadias | 4 | 2011 | 26 | 0.910 |
Why?
| | Seminoma | 3 | 2021 | 17 | 0.900 |
Why?
| | Sarcoma, Clear Cell | 2 | 2023 | 6 | 0.900 |
Why?
| | Urologic Surgical Procedures, Male | 4 | 2018 | 27 | 0.880 |
Why?
| | Spermatic Cord Torsion | 2 | 2013 | 4 | 0.870 |
Why?
| | Sarcoma | 2 | 2022 | 137 | 0.870 |
Why?
| | Leydig Cell Tumor | 3 | 2021 | 8 | 0.860 |
Why?
| | Disease-Free Survival | 7 | 2022 | 649 | 0.830 |
Why?
| | Paraganglioma | 1 | 2022 | 48 | 0.830 |
Why?
| | Cryptorchidism | 2 | 2019 | 12 | 0.820 |
Why?
| | Age Factors | 12 | 2019 | 2995 | 0.800 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 7 | 0.790 |
Why?
| | Tomography, X-Ray Computed | 9 | 2021 | 2436 | 0.790 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 122 | 0.780 |
Why?
| | Pheochromocytoma | 2 | 2019 | 54 | 0.770 |
Why?
| | Infant, Newborn | 11 | 2023 | 5255 | 0.760 |
Why?
| | Surgeons | 3 | 2023 | 243 | 0.760 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 4 | 0.730 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 2 | 2017 | 5 | 0.710 |
Why?
| | Cystectomy | 1 | 2019 | 32 | 0.710 |
Why?
| | Neoplasm Invasiveness | 7 | 2017 | 462 | 0.710 |
Why?
| | Smooth Muscle Myosins | 1 | 2019 | 9 | 0.700 |
Why?
| | Molecular Targeted Therapy | 2 | 2013 | 356 | 0.700 |
Why?
| | Muscle Relaxation | 1 | 2019 | 32 | 0.700 |
Why?
| | Myosin Light Chains | 1 | 2019 | 35 | 0.690 |
Why?
| | Diagnostic Imaging | 3 | 2022 | 294 | 0.670 |
Why?
| | Neoadjuvant Therapy | 4 | 2021 | 333 | 0.670 |
Why?
| | Treatment Outcome | 25 | 2022 | 9342 | 0.660 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 114 | 0.660 |
Why?
| | Radiotherapy | 1 | 2019 | 187 | 0.660 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 51 | 0.650 |
Why?
| | Specimen Handling | 1 | 2019 | 165 | 0.650 |
Why?
| | Catheterization | 1 | 2019 | 163 | 0.650 |
Why?
| | von Hippel-Lindau Disease | 1 | 2018 | 12 | 0.650 |
Why?
| | Testicular Diseases | 1 | 2018 | 6 | 0.650 |
Why?
| | Health Care Surveys | 2 | 2017 | 546 | 0.630 |
Why?
| | Calculi | 1 | 2018 | 14 | 0.630 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2019 | 900 | 0.630 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 455 | 0.630 |
Why?
| | Conservative Treatment | 1 | 2018 | 31 | 0.620 |
Why?
| | Orchiopexy | 3 | 2019 | 5 | 0.620 |
Why?
| | Cancer Survivors | 1 | 2021 | 201 | 0.610 |
Why?
| | Critical Pathways | 1 | 2018 | 79 | 0.610 |
Why?
| | Radiation Exposure | 1 | 2017 | 44 | 0.610 |
Why?
| | Kaplan-Meier Estimate | 6 | 2019 | 842 | 0.600 |
Why?
| | Risk Assessment | 10 | 2018 | 3057 | 0.590 |
Why?
| | Cytodiagnosis | 1 | 2017 | 27 | 0.590 |
Why?
| | Frozen Sections | 1 | 2017 | 24 | 0.590 |
Why?
| | Kidney Medulla | 1 | 2016 | 32 | 0.590 |
Why?
| | Surveys and Questionnaires | 3 | 2018 | 4708 | 0.590 |
Why?
| | Surgical Oncology | 1 | 2016 | 14 | 0.590 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2220 | 0.580 |
Why?
| | Angiomyolipoma | 1 | 2016 | 18 | 0.580 |
Why?
| | Postoperative Care | 1 | 2018 | 237 | 0.580 |
Why?
| | Teratoma | 2 | 2017 | 92 | 0.580 |
Why?
| | Robotic Surgical Procedures | 2 | 2015 | 89 | 0.570 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 38 | 0.570 |
Why?
| | Muscle Contraction | 1 | 2019 | 413 | 0.560 |
Why?
| | Neoplasms | 4 | 2023 | 2179 | 0.550 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 11 | 0.550 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1390 | 0.540 |
Why?
| | Adult | 22 | 2020 | 31512 | 0.540 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 683 | 0.530 |
Why?
| | Survival Analysis | 5 | 2019 | 1267 | 0.520 |
Why?
| | Pediatricians | 1 | 2016 | 120 | 0.520 |
Why?
| | Adenoma | 1 | 2016 | 191 | 0.510 |
Why?
| | Neurofibromatosis 1 | 2 | 2019 | 37 | 0.510 |
Why?
| | Pelvic Neoplasms | 2 | 2013 | 20 | 0.490 |
Why?
| | Cause of Death | 1 | 2016 | 380 | 0.490 |
Why?
| | Prostatic Neoplasms | 2 | 2019 | 940 | 0.490 |
Why?
| | Ovarian Neoplasms | 3 | 2021 | 420 | 0.480 |
Why?
| | Databases, Factual | 5 | 2019 | 1231 | 0.480 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2012 | 2062 | 0.470 |
Why?
| | Hypertension | 1 | 2022 | 1203 | 0.470 |
Why?
| | Acute-Phase Proteins | 1 | 2013 | 67 | 0.460 |
Why?
| | Lipocalins | 1 | 2013 | 38 | 0.460 |
Why?
| | Societies, Medical | 4 | 2018 | 703 | 0.460 |
Why?
| | SEER Program | 5 | 2019 | 205 | 0.450 |
Why?
| | Ultrasonography | 5 | 2019 | 716 | 0.450 |
Why?
| | Radiation Protection | 1 | 2013 | 36 | 0.450 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2013 | 66 | 0.450 |
Why?
| | Patient Education as Topic | 1 | 2018 | 699 | 0.440 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 402 | 0.440 |
Why?
| | Fertility Preservation | 2 | 2023 | 47 | 0.430 |
Why?
| | Biopsy, Needle | 1 | 2013 | 190 | 0.430 |
Why?
| | Multimodal Imaging | 1 | 2013 | 100 | 0.430 |
Why?
| | Retroperitoneal Space | 1 | 2012 | 15 | 0.420 |
Why?
| | Glucose Transporter Type 1 | 1 | 2012 | 42 | 0.420 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 544 | 0.410 |
Why?
| | Incidence | 7 | 2019 | 2424 | 0.410 |
Why?
| | Follow-Up Studies | 11 | 2019 | 4596 | 0.400 |
Why?
| | Survival Rate | 6 | 2024 | 1720 | 0.400 |
Why?
| | United States | 12 | 2021 | 12555 | 0.400 |
Why?
| | Primary Prevention | 1 | 2013 | 185 | 0.400 |
Why?
| | Codon | 1 | 2011 | 89 | 0.400 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 298 | 0.400 |
Why?
| | Proline | 1 | 2011 | 71 | 0.400 |
Why?
| | Multivariate Analysis | 5 | 2018 | 1474 | 0.390 |
Why?
| | Seasons | 1 | 2013 | 461 | 0.380 |
Why?
| | Vena Cava, Inferior | 1 | 2011 | 55 | 0.380 |
Why?
| | Combined Modality Therapy | 4 | 2023 | 1166 | 0.380 |
Why?
| | Suburethral Slings | 1 | 2010 | 5 | 0.380 |
Why?
| | Temperature | 1 | 2013 | 622 | 0.370 |
Why?
| | Arginine | 1 | 2011 | 249 | 0.370 |
Why?
| | Hernia, Ventral | 1 | 2010 | 19 | 0.360 |
Why?
| | Breast Neoplasms | 1 | 2022 | 1965 | 0.360 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2010 | 32 | 0.360 |
Why?
| | Urinary Incontinence | 1 | 2010 | 61 | 0.360 |
Why?
| | Prospective Studies | 8 | 2021 | 6471 | 0.350 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 618 | 0.350 |
Why?
| | Ureter | 4 | 2014 | 32 | 0.350 |
Why?
| | Mouth Mucosa | 1 | 2009 | 82 | 0.350 |
Why?
| | Skin Transplantation | 1 | 2009 | 58 | 0.350 |
Why?
| | Campomelic Dysplasia | 1 | 2009 | 2 | 0.350 |
Why?
| | Dysgerminoma | 1 | 2009 | 3 | 0.350 |
Why?
| | Attitude of Health Personnel | 1 | 2016 | 992 | 0.350 |
Why?
| | Recovery of Function | 1 | 2013 | 604 | 0.350 |
Why?
| | Urolithiasis | 1 | 2009 | 8 | 0.350 |
Why?
| | Brachytherapy | 2 | 2021 | 103 | 0.340 |
Why?
| | Urethra | 2 | 2011 | 58 | 0.340 |
Why?
| | Angiogenesis Inhibitors | 1 | 2011 | 219 | 0.340 |
Why?
| | Bone Neoplasms | 1 | 2011 | 199 | 0.340 |
Why?
| | Clitoris | 1 | 2009 | 9 | 0.340 |
Why?
| | Venous Thrombosis | 1 | 2011 | 147 | 0.340 |
Why?
| | SOX9 Transcription Factor | 1 | 2009 | 24 | 0.340 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 709 | 0.330 |
Why?
| | Aged | 11 | 2021 | 19657 | 0.330 |
Why?
| | Surgical Flaps | 1 | 2009 | 118 | 0.330 |
Why?
| | Time Factors | 8 | 2019 | 6412 | 0.320 |
Why?
| | Middle Aged | 12 | 2021 | 27617 | 0.300 |
Why?
| | Risk Factors | 8 | 2018 | 9000 | 0.300 |
Why?
| | Health Promotion | 1 | 2013 | 691 | 0.290 |
Why?
| | Calcinosis | 1 | 2009 | 282 | 0.280 |
Why?
| | Ureterocele | 2 | 2016 | 7 | 0.270 |
Why?
| | Vesico-Ureteral Reflux | 2 | 2016 | 21 | 0.270 |
Why?
| | Mitotic Index | 2 | 2015 | 27 | 0.260 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 811 | 0.260 |
Why?
| | Hypertrophy | 2 | 2019 | 121 | 0.260 |
Why?
| | Kidney Diseases | 1 | 2009 | 439 | 0.250 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2013 | 360 | 0.240 |
Why?
| | Gonadal Dysgenesis | 1 | 2023 | 9 | 0.230 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2014 | 158 | 0.230 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 134 | 0.220 |
Why?
| | Pubic Bone | 1 | 2022 | 4 | 0.220 |
Why?
| | Algorithms | 1 | 2009 | 1541 | 0.210 |
Why?
| | Urination | 1 | 2022 | 39 | 0.210 |
Why?
| | Sex Factors | 2 | 2017 | 1781 | 0.210 |
Why?
| | Infertility | 1 | 2022 | 45 | 0.210 |
Why?
| | Sertoli Cell Tumor | 1 | 2021 | 2 | 0.200 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 23 | 0.200 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2022 | 118 | 0.200 |
Why?
| | Testosterone | 2 | 2015 | 351 | 0.200 |
Why?
| | Reoperation | 3 | 2014 | 557 | 0.200 |
Why?
| | Aniridia | 1 | 2020 | 5 | 0.200 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2019 | 71 | 0.200 |
Why?
| | PAX6 Transcription Factor | 1 | 2020 | 23 | 0.200 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 29 | 0.190 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1384 | 0.190 |
Why?
| | Codon, Nonsense | 1 | 2020 | 38 | 0.190 |
Why?
| | Interleukin-2 | 1 | 2022 | 416 | 0.190 |
Why?
| | Eye Proteins | 1 | 2020 | 77 | 0.190 |
Why?
| | Pneumothorax | 1 | 2021 | 48 | 0.190 |
Why?
| | Syndrome | 1 | 2021 | 344 | 0.180 |
Why?
| | Penile Neoplasms | 1 | 2019 | 7 | 0.180 |
Why?
| | Priapism | 1 | 2019 | 9 | 0.180 |
Why?
| | Patient Selection | 3 | 2013 | 676 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2275 | 0.180 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 42 | 0.180 |
Why?
| | Proportional Hazards Models | 3 | 2011 | 1125 | 0.180 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2019 | 10 | 0.180 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2019 | 9 | 0.180 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2019 | 26 | 0.180 |
Why?
| | Decision Trees | 1 | 2019 | 83 | 0.170 |
Why?
| | Computers | 1 | 2019 | 64 | 0.170 |
Why?
| | Puberty, Precocious | 1 | 2019 | 14 | 0.170 |
Why?
| | Genetic Testing | 2 | 2019 | 389 | 0.170 |
Why?
| | Dermatofibrosarcoma | 1 | 2018 | 9 | 0.170 |
Why?
| | Hospitals | 1 | 2023 | 598 | 0.170 |
Why?
| | Genotype | 2 | 2016 | 1882 | 0.170 |
Why?
| | Aged, 80 and over | 4 | 2019 | 6561 | 0.170 |
Why?
| | Diagnostic Errors | 1 | 2019 | 162 | 0.160 |
Why?
| | Self-Examination | 1 | 2018 | 1 | 0.160 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 119 | 0.160 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 200 | 0.160 |
Why?
| | Proton Therapy | 1 | 2018 | 10 | 0.160 |
Why?
| | General Surgery | 1 | 2019 | 134 | 0.160 |
Why?
| | Mutation | 1 | 2009 | 3457 | 0.160 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 189 | 0.160 |
Why?
| | Preoperative Period | 1 | 2018 | 110 | 0.160 |
Why?
| | Feasibility Studies | 2 | 2018 | 749 | 0.150 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 14 | 0.150 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 81 | 0.150 |
Why?
| | Ultrasonography, Doppler | 1 | 2018 | 104 | 0.150 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.150 |
Why?
| | Unnecessary Procedures | 1 | 2017 | 45 | 0.150 |
Why?
| | Testis | 1 | 2018 | 144 | 0.150 |
Why?
| | Analysis of Variance | 2 | 2017 | 1293 | 0.150 |
Why?
| | Intraoperative Period | 1 | 2017 | 55 | 0.150 |
Why?
| | Europe | 1 | 2018 | 356 | 0.150 |
Why?
| | Postoperative Complications | 4 | 2023 | 2235 | 0.150 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 250 | 0.140 |
Why?
| | Logistic Models | 3 | 2018 | 1901 | 0.140 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 349 | 0.140 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1206 | 0.140 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.140 |
Why?
| | North America | 1 | 2016 | 266 | 0.140 |
Why?
| | Certification | 1 | 2016 | 99 | 0.140 |
Why?
| | Length of Stay | 2 | 2018 | 1032 | 0.140 |
Why?
| | Translocation, Genetic | 2 | 2018 | 92 | 0.130 |
Why?
| | Antineoplastic Agents | 2 | 2018 | 1974 | 0.130 |
Why?
| | Models, Statistical | 1 | 2019 | 636 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1440 | 0.130 |
Why?
| | Learning | 1 | 2019 | 374 | 0.130 |
Why?
| | History, 21st Century | 1 | 2015 | 170 | 0.130 |
Why?
| | Phosphorylation | 1 | 2019 | 1633 | 0.130 |
Why?
| | Registries | 2 | 2019 | 1810 | 0.120 |
Why?
| | Matched-Pair Analysis | 1 | 2014 | 39 | 0.120 |
Why?
| | Forecasting | 1 | 2016 | 353 | 0.120 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2014 | 16 | 0.120 |
Why?
| | Ureteral Calculi | 1 | 2014 | 13 | 0.120 |
Why?
| | Genitalia, Female | 1 | 2014 | 40 | 0.120 |
Why?
| | TRPM Cation Channels | 1 | 2014 | 68 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3174 | 0.120 |
Why?
| | Kidney Function Tests | 1 | 2014 | 164 | 0.120 |
Why?
| | Lipocalin-2 | 1 | 2013 | 64 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 403 | 0.110 |
Why?
| | Disease Management | 1 | 2017 | 571 | 0.110 |
Why?
| | Estrogens | 1 | 2015 | 328 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2020 | 867 | 0.110 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 1059 | 0.110 |
Why?
| | Cohort Studies | 5 | 2016 | 5116 | 0.110 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 52 | 0.110 |
Why?
| | Spermatic Cord | 1 | 2012 | 1 | 0.110 |
Why?
| | Blood Vessels | 1 | 2014 | 187 | 0.110 |
Why?
| | Creatinine | 1 | 2014 | 491 | 0.110 |
Why?
| | Radiation Dosage | 1 | 2013 | 147 | 0.110 |
Why?
| | Fetal Diseases | 1 | 2013 | 148 | 0.100 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 4552 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 271 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 195 | 0.100 |
Why?
| | Surgical Wound Dehiscence | 1 | 2011 | 19 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2018 | 762 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2016 | 648 | 0.100 |
Why?
| | Autophagy | 1 | 2014 | 315 | 0.100 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 58 | 0.100 |
Why?
| | Animals | 4 | 2022 | 33381 | 0.100 |
Why?
| | Clinical Competence | 1 | 2017 | 951 | 0.100 |
Why?
| | Thrombectomy | 1 | 2011 | 60 | 0.090 |
Why?
| | Bevacizumab | 1 | 2011 | 124 | 0.090 |
Why?
| | Texas | 1 | 2011 | 186 | 0.090 |
Why?
| | Sulfonamides | 1 | 2014 | 445 | 0.090 |
Why?
| | Compliance | 1 | 2010 | 44 | 0.090 |
Why?
| | Rectum | 1 | 2011 | 157 | 0.090 |
Why?
| | Pyrroles | 1 | 2011 | 191 | 0.090 |
Why?
| | Internship and Residency | 1 | 2019 | 1001 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 525 | 0.090 |
Why?
| | Operative Time | 3 | 2014 | 114 | 0.090 |
Why?
| | Muscle, Smooth | 1 | 2010 | 157 | 0.090 |
Why?
| | Pilot Projects | 1 | 2014 | 1419 | 0.090 |
Why?
| | Penis | 2 | 2019 | 37 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1012 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 736 | 0.080 |
Why?
| | Indoles | 1 | 2011 | 316 | 0.080 |
Why?
| | Alleles | 1 | 2011 | 832 | 0.080 |
Why?
| | Remission, Spontaneous | 2 | 2021 | 37 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 861 | 0.080 |
Why?
| | MicroRNAs | 1 | 2014 | 637 | 0.080 |
Why?
| | Congenital Abnormalities | 1 | 2008 | 74 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1868 | 0.080 |
Why?
| | Biomarkers | 2 | 2019 | 3588 | 0.080 |
Why?
| | Mice | 2 | 2022 | 15520 | 0.070 |
Why?
| | Pregnancy | 1 | 2018 | 5690 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2012 | 516 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2014 | 3171 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 667 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2674 | 0.070 |
Why?
| | Signal Transduction | 1 | 2019 | 4709 | 0.070 |
Why?
| | Cystoscopy | 2 | 2016 | 16 | 0.070 |
Why?
| | Anaplasia | 1 | 2024 | 2 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1284 | 0.060 |
Why?
| | Nephroureterectomy | 1 | 2023 | 2 | 0.060 |
Why?
| | Sexual Development | 1 | 2023 | 20 | 0.060 |
Why?
| | Gonads | 1 | 2023 | 29 | 0.060 |
Why?
| | Germany | 1 | 2020 | 89 | 0.050 |
Why?
| | Accreditation | 1 | 2019 | 87 | 0.040 |
Why?
| | Hyperplasia | 1 | 2019 | 170 | 0.040 |
Why?
| | Mohs Surgery | 1 | 2018 | 25 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 26 | 0.040 |
Why?
| | Perioperative Care | 1 | 2019 | 132 | 0.040 |
Why?
| | Mosaicism | 1 | 2017 | 62 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2018 | 310 | 0.040 |
Why?
| | Ureteroscopy | 1 | 2016 | 16 | 0.040 |
Why?
| | Monitoring, Intraoperative | 1 | 2016 | 43 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 399 | 0.030 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 11 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2014 | 23 | 0.030 |
Why?
| | Ureterostomy | 1 | 2014 | 3 | 0.030 |
Why?
| | Oncogenes | 1 | 2014 | 111 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 245 | 0.030 |
Why?
| | Cicatrix | 1 | 2014 | 53 | 0.030 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 3 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 460 | 0.030 |
Why?
| | Mice, Nude | 1 | 2014 | 663 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 460 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2014 | 625 | 0.030 |
Why?
| | Pain, Postoperative | 1 | 2013 | 211 | 0.030 |
Why?
| | Quality of Life | 1 | 2022 | 2366 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2011 | 28 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2011 | 258 | 0.020 |
Why?
| | Area Under Curve | 1 | 2011 | 296 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1795 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 177 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 332 | 0.020 |
Why?
| | Dihydrolipoamide Dehydrogenase | 1 | 2009 | 7 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1167 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 2851 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2013 | 794 | 0.020 |
Why?
|
|
Cost's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|